IPOs

Neoantigen pioneer Neon Therapeutics casts off in search of $115M IPO to fuel the race to a personalized cancer treatment

Can a bespoke cancer vaccine actually succeed in treating individual oncology cases? 

Eric Lander

Neon Therapeutics launched three years ago, setting out on a mission to prove that it could, and it now has enough examples of a select handful of individual responses to their neoantigen platform to gamble that investors will come in to back a $115 million IPO as they look to transition from their first exploratory human studies into advanced development work.

Over the startup period, Neon has been developing its first peptide-based individualized cancer vaccines, working with the mutations present in each case. Their work has steered them toward a set of cancers like non-small cell lung cancer, which have a high mutation burden and a rich set of individual antigen targets to select from.

By zeroing in on these neoantigens, they say, they can make the first generation of checkpoint inhibitors — designed to unleash a swarm of T cells on cancer cells — far more effective. But groundbreaking new technologies like these also require their own manufacturing base, and they won’t come cheap.

Catherine Wu, Neon Therapeutics

Third Rock launched Neon Therapeutics with a high council of prominent scientists from Dana-Farber, MIT and elsewhere. The advisory group included Eric Lander from the Broad Institute of MIT and Harvard, MD Anderson’s Jim Allison and Catherine Wu with Dana-Farber. In true Third Rock style they recruited Novartis vet Hugh O’Dowd to come in and take the helm, and the VC group still owns 44.4% of the equity.

Access Industries weighs in at 12% with Fidelity at 7.5% and Partner Fund Management at 7%. O’Dowd has a 2.6% slice.

Neon has burned through $111 million to get to this stage, and the team has $62 million in reserve. A success here would extend their runway considerably, if they can get enough support for what remains a high-risk effort to break serious new ground in oncology.

Not at all unsurprisingly in an era of rampant I/O enthusiasm, Neon is also busy in a field crowded with would-be pioneers. The most prominent group includes Aduro Biotech, Advaxis, Agenus, BioNTech AG, Gritstone Oncology, Moderna Therapeutics, PACT Pharma, and Ziopharm.

Neon plans to trade as $NTGN.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription


Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->